Suncoast Ventures

Managing Partner Genevieve LeMarchal leads investment decisions. She built the firm's investment model after running Expert Dojo's healthcare accelerator and serving as a GP at FoundersPad VC Fund II. The venture partner bench includes former operators like Dr. Ray Costantini (Bright.MD) and Hal Walbrink (Xinetix), but the firm's website does not detail a formal investment committee structure.

Suncoast's sourcing appears driven by its operator-heavy team. Venture partners include practicing clinicians, medical device entrepreneurs, and former health system executives whose networks span hospitals, universities, and portfolio companies. The firm's website lists no systematic inbound channels, but explicitly instructs startups not to use the contact form for pitches, suggesting a referral-based or proactive sourcing model.

Suncoast Ventures operates as a traditional early-stage venture firm, not a family office. It was founded in 2021 by a group of engineers and entrepreneurs. The firm does not disclose its limited partners or fund structure publicly, but its portfolio composition — 17 named companies with institutional co-investors like Mayo Clinic and the Gates Foundation — aligns with a standard venture capital fund model.

Based on disclosed information, Suncoast engages only in direct investments, not fund-of-fund commitments. Every named portfolio company on the firm's website is a direct operating company. The firm co-invests alongside other venture funds and institutional investors, suggesting a direct-deal syndication approach rather than allocating capital to other fund managers.

Suncoast targets early-stage healthcare companies from seed to growth. The firm's own description mentions early stage, seed, and startup phases, while its portfolio includes companies ranging from pre-revenue therapeutics to growth-stage digital health platforms. Specific round participation is not disclosed per company, but co-investors like Techstars and Cedars-Sinai Accelerator indicate seed-stage activity.

Suncoast has not published explicit exclusion criteria. Its portfolio is entirely healthcare-focused, with no disclosed investments outside digital health, medtech, medical AI, consumer health, and life sciences. The firm's stated thesis — "$1B healthcare problems hiding in plain sight" — and its clinical operator team composition strongly indicate a singular healthcare mandate, effectively excluding sectors like fintech, enterprise software, or climate.

Suncoast has not disclosed any philanthropic foundation, donor-advised fund, or impact vehicle. Some venture partners, like Tammy Mahaney, have personal involvement in global health missions and community volunteering, but these activities appear separate from the firm's investment operations. No formal philanthropic allocation or structure is referenced on the firm's website.